Breaking Research News from Breastcancer.org
Comments
-
Verzenio Plus Faslodex Improves Overall Survival by 9 Months in Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer
September 30, 2019
Latest results from MONARCH 2 study show adding Verzenio to Faslodex improves overall survival by 9 months for advanced-stage, hormone-receptor-positive, HER2-negative breast cancer. Read more...0 -
Kisqali Plus Faslodex Improves Overall Survival in Advanced-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer
October 2, 2019
Latest MONALEESA-3 results show Kisqali and Faslodex offer better overall survival than Faslodex alone in postmenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer that either hadn't been treated yet or had been treated with only one hormonal therapy. Read more...0 -
Adding Keytruda to Chemotherapy Before Surgery for Early-Stage, Triple-Negative Breast Cancer Improves Response to Treatment
October 2, 2019
The combination of the immunotherapy Keytruda and chemotherapy before surgery to remove early-stage, triple-negative breast cancer led to a better pathologic complete response than chemotherapy alone. Read more...0 -
Multigene Testing of Everyone Diagnosed With Breast Cancer Deemed Cost-Effective, and Researchers Say Policies Should Change
October 8, 2019
A study found testing all people diagnosed with breast cancer for mutations in three genes linked to a high risk of the disease — BRCA1, BRCA2, and PALB2 — would be "extremely cost-effective" compared to testing based on family history or clinical guidelines in the United States and the United Kingdom. Read more...0 -
Low Vitamin D Levels Found in Irish Women Diagnosed With Breast Cancer
October 14, 2019
A small study found that more than half of Irish women being treated with chemotherapy for breast cancer had lower-than-recommended levels of vitamin D. Read more...0 -
Treatment of Male Breast Cancer Has Evolved, Study Shows
October 14, 2019
While there have been no clinical trials specifically focused on male breast cancer in the United States, treatment of this disease has evolved over the years and researchers now know factors linked to better survival. Read more...0 -
Experts Update Exercise Guidelines for People Treated for Cancer
October 23, 2019
The American College of Sports Medicine updated its guidelines on exercise for cancer prevention, as well as guidelines on exercise to ease a number of treatment side effects. Read more...0 -
Sentinel Lymph Node Biopsy Offers No Benefits for Older Women With DCIS
October 30, 2019
For older women diagnosed with DCIS, adding sentinel lymph node biopsy to lumpectomy didn't reduce the risk of dying from breast cancer, didn't lower the risk of being diagnosed with invasive breast cancer, and didn't reduce the number of additional cancer treatments a woman had. Read more...0 -
CDK4/6 Inhibitor Plus Aromatase Inhibitor Helps Treat Breast Cancer, No Matter a Woman's Age
November 5, 2019
An analysis of three studies on different CDK4/6 inhibitors in combination with an aromatase inhibitor to treat postmenopausal women diagnosed with metastatic, hormone-receptor-positive, HER2-negative breast cancer found the treatment combination was effective in both younger and older women. Read more...0 -
Supplemental MRI Screening May Benefit Women With Extremely Dense Breasts
December 3, 2019
Screening with MRI in between regular screening mammograms may improve breast cancer detection in women with extremely dense breasts. Read more...0 -
Permanent Hair Dyes, Straighteners Linked to Higher Breast Cancer Risk
December 10, 2019
Research suggests that permanent hair dye and chemical hair straighteners could increase breast cancer risk, especially for black women. Read more...0 -
Experimental Tucatinib Improves Survival in Metastatic HER2-Positive Breast Cancer, May Be New Standard of Care
December 17, 2019
Adding experimental tucatinib to the standard of care of Herceptin and Xeloda improved both progression-free survival and overall survival in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated with Herceptin, Perjeta, and Kadcyla. Read more...0 -
Immunotherapy for Early-Stage Triple-Negative Breast Cancer: Understanding What Appear to Be Conflicting Results
December 19, 2019
Results from two studies on using the immunotherapy medicines Tecentriq or Keytruda along with chemotherapy to treat early-stage triple-negative breast cancer before surgery suggested that Keytruda offered benefits while Tecentriq did not. Read more...0 -
Risk-Reducing Effects of Arimidex for High-Risk Postmenopausal Women Last Years After Treatment Stops
December 19, 2019
Postmenopausal women at high risk for breast cancer who hadn't been diagnosed continued to get risk-reducing benefits for at least 11 years after they stopped taking Arimidex preventively. Read more...0 -
Subcutaneous Herceptin and Perjeta Combined With Chemo Before Breast Cancer Surgery Offers Same Benefits as IV Versions
December 20, 2019
A fixed-dose combination of Herceptin and Perjeta given as an injection in the thigh along with chemotherapy before surgery seems to offer the same benefits as IV infusions of the two medicines for people diagnosed with early-stage HER2-positive breast cancer. Read more...0 -
Is Oral Paclitaxel Better Than IV Paclitaxel for Metastatic Breast Cancer?
January 2, 2020
Women diagnosed with metastatic breast cancer treated with an oral form of paclitaxel seemed to have a better response to treatment and less neuropathy compared to women treated with the IV version of paclitaxel. Read more...0 -
FDA Approves Enhertu for Unresectable or Pretreated Metastatic HER2-Positive Breast Cancer
January 2, 2020
On Dec. 20, 2019, the U.S. Food and Drug Administration approved Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki) to treat people diagnosed with unresectable HER2-positive breast cancer or metastatic HER2-positive breast cancer that has been treated with two or more anti-HER2 therapies. Read more...0 -
Adding Perjeta to Herceptin and Chemotherapy After Surgery Shows Benefits in Early-Stage HER2-Positive Breast Cancer
January 3, 2020
Updated results show adding Perjeta to Herceptin and chemotherapy after surgery for early-stage HER2-positive breast cancer continues to reduce the risk of recurrence and to slightly improve survival. Read more..0 -
Breast Cancers Found by Yearly Mammograms Smaller, Less Advanced Than Cancers Found by Mammograms Every 2 Years
January 3, 2020
Women diagnosed with breast cancer after having yearly mammograms were diagnosed with cancers that were smaller and less advanced than women who had mammograms every 2 years. Read more...0 -
Study Links Sustained Weight Loss After 50 to Lower Breast Cancer Risk
January 6, 2020
A study suggests that women age 50 and older who lost weight and kept it off have a lower risk of breast cancer than women whose weight remained the same. Read more...0 -
Things are changing! "Innovators have invented a better way for surgeons to locate tumors during lumpectomies for breast cancer."
0 -
I didn’t know this is how surgery works! Wow this is great! I haven’t had any surgery.
0 -
The new guidelines decrease the amount of exercise previously stated needed to reduce breast cancer and chance of recurrence. If I follow the new guidelines, am I equally protected?
0 -
At-Home Genetic Tests Miss Many Mutations Linked to Cancer, Especially in Ethnic Minorities
January 7, 2020
At-home genetic tests are giving many people false-negative results for genetic mutations linked to breast, ovarian, and colorectal cancer. For some ethnic minorities, the risk of missing a cancer-linked mutation could be as high as 100%. Read more...0 -
U.S. Black Men Have Higher Rates of All Types of Breast Cancer Compared to White Men
January 7, 2020
Black men have higher rates of all types of breast cancer compared to white men in the United States. Read more...0 -
Taking Certain Supplements Before and During Chemotherapy for Breast Cancer May Be Risky
January 9, 2020
A small study suggests that people who took antioxidant supplements before and during chemotherapy to treat breast cancer may have a higher risk of recurrence and death. Read more...0 -
Long-Term Follow-Up Suggests Estrogen-Only and Combination Hormone Replacement Therapy Have Opposite Effects on Breast Cancer Risk
January 9, 2020
Estrogen-only hormone replacement therapy seems to lower breast cancer risk, while combination hormone replacement therapy increases risk, according to long-term data from the Women's Health Initiative. Read more...0 -
Estrogen-Receptor-Negative, Progesterone-Receptor-Positive Breast Cancers: A Distinct Subtype?
January 13, 2020
Breast cancers that estrogen-receptor-negative and progesterone-receptor-positive should be considered a distinct breast cancer subtype, according to a study. Read more...0 -
Racial Disparities in Breast Cancer Stage at Diagnosis Linked to Lack of Insurance
January 14, 2020
A large percentage of the difference in breast cancer stage at diagnosis between white women and women of other ethnicities seems to be affected by whether a woman has insurance. Read more...0 -
More Evidence That Chemotherapy Before Surgery Can Make Triple-Negative Breast Cancer Eligible for Lumpectomy
January 15, 2020
About half of women diagnosed with early-stage triple-negative breast cancer who were not eligible for lumpectomy when first diagnosed became eligible for lumpectomy after neoadjuvant chemotherapy. Read more...0
